Toward the Identification of Distinct Molecular and Clinical Entities of Multiple Myeloma Using Global Gene Expression Profiling

Seminars in Hematology

Volumn 40, Issue 4, 2003, Pages 308-320

  Zhan, Fenghuang ^b   Barlogie, Bart ^b   Shaughnessy Jr , John ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME DELETION 13; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; DISEASE COURSE; GENE EXPRESSION PROFILING; HUMAN; MOLECULAR BIOLOGY; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0142094496     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(03)00197-5     Document Type: Article

References (37)

1. Alizadeh AA, Eisen MB, Davis RE: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000
2. Barlogie B, Shaughnessy J, Munshi N, et al: Plasma cell myeloma, in Beutler E, Lichtman M, Coller B, et al (eds): Hematology. William's Hematology (ed 6). New York, NY, McGraw-Hill, 2001
3. Calin GA, Dumitru CD, Shimizu M, et al: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99:15524-15529, 2002
4. Flactif M, Zandecki M, Lai JL, et al: Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia 9:2109-2114, 1995
5. Ge N-L, Rudikoff S: Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 96:2856-2861, 2000
6. Georgii-Hemming P, Wiklund HJ, Ljunggren O, et al: Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 88:2250-2258, 1996
7. Goss KH, Risinger MA, Kordich JJ, et al: Enhanced tumor formation in mice heterozygous for Blm mutation. Science 297:2051-2053, 2002
8. Gruber SB, Ellis NA, Scott KK, et al: BLM heterozygosity and the risk of colorectal cancer. Science 297:2013, 2002
9. Jacobson J, Zhan F, Sawyer J, et al: Gene expression reflects changes in ploidy of some, but not all chromosomes, in multiple myeloma. Blood 100:1225a, 2002 (suppl 1, abstr)
10. Kuehl WM, Bergsagel PL: Multiple myeloma: Evolving genetic events and host interactions. Nature Rev Cancer 2:175-187, 2002
11. Kyle RA, Therneau TM, Rajkumar SV, et al: A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564-569, 2002
12. Latreille J, Barlogie B, Dosik G, et al: Cellular DNA content as a marker of human multiple myeloma. Blood 55:403-408, 1980
13. Lin H, Liu XY, Subramanian B, et al: Mitotic arrest induced by XK469, a novel antitumor agent, is correlated with the inhibition of cyclin B1 ubiquitination. Int J Cancer 97:121-128, 2002
14. Mabuchi H, Fujii H, Calin G, et al: Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia. Cancer Res 61:2870-2877, 2001
15. + B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis. Blood 88:622-632, 1996
16. Medina F, Segundo C, Campos-Caro A, et al: The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood 99:2154-2161, 2002
17. Mertens D, Wolf S, Schroeter P, et al: Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia. Blood 99:4116-4121, 2002
18. Migliazza A, Bosch F, Komatsu H, et al: Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood 97:2098-2104, 2001
19. Munshi N, Tricot G, Barlogie B: Plasma cell neoplasms, in DeVita VT, Hellman S, Rosenberg S (eds): Cancer Principles and Practice of Oncology. Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 2465-2499
20. Qiang Y-W, Kopantzev E, Rudikoff S: Insulinlike growth factor-I signaling in multiple myeloma: Downstream elements, functional correlates, and pathway cross-talk. Blood 99:4138-4146, 2002
21. San Miguel JF, Garcia-Sanz R, Gonzalez M, et al: Immuno-phenotype and DNA cell content in myeloma. Baillieres Clin Haematol 8:735-759, 1995
22. Santra M, Zhan F, Tian E, et al: A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lack FGFR3 expression but maintain an IGH/mmset fusion transcript. Blood 101:2374-2376, 2003
23. Shaughnessy J Jr, Gabrea A, Qi Y, et al: Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 98:217-223, 2001
24. Shaughnessy J, Barlogie B, Zhan F, et al: Continuous absence of metaphase abnormalities especially of chromosome 13 and hypodiploidy assures long term survival in multiple myeloma treated with Total Therapy I: Interpreted in the context of gene expression profiling. Blood 102:592-600, 2003
25. Shaughnessy J, Tian E, Sawyer J, et al: Prognostic impact of cytogenetic and interphase FISH defined chromosome 13 deletion in multiple myeloma: Early results of total therapy II. Br J Haematol 120:44-52, 2003
26. Shaughnessy J, Tian E, Sawyer J, et al: High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 96:1505-1511, 2000
27. Shaughnessy J, Zhan F, McCastlain K, et al: Gene expression profiling in the prediction of response of multiple myeloma to the proteasome inhibitor PS-341. Blood 100:1512a, 2002 (suppl 1, abstr)
28. Standal T, Borset M, Lenhoff S, et al: Serum insulin like growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood 100:3925-3929, 2002
29. Tarte K, De Vos J, Thykjaer T, et al: Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood 100:1113-1122, 2002
30. Tarte K, De Vos J, Zhan F, et al: Gene expression profiling of plasma cells and plasmablasts: Toward a better understanding of the late stages of B-cell differentiation, Blood (submitted)
31. Tian E, Zhan F, Barlogie B, et al: The transcription repressor, TGF-β stimulated clone (TSC-22), is a candidate for the 13q14 multiple myeloma tumor suppressor gene. Blood 98:3221a, 2001 (suppl 1, abstr)
32. Tibshirani R, Hastie T, Narasimhan B, et al: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 99:6567-6572, 2002
33. Townsley F, Aristarkhov A, Beck S, et al: Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proc Natl Acad Sci USA 94:2362-2367, 1997
34. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116-5121, 2001
35. Zhan F, Hardin J, Kordsmeier B, et al: Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99:1745-1757, 2002
36. Zhan F, Tian E, Bumm K, et al: Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late stage B-cell development. Blood 101:1128-1140, 2003
37. Zhan F, Walker R, Santra M, et al: Gene expression profiles can identify known and suspected multiple myeloma associated 14q32 translocations. Blood 100:1190a, 2002 (suppl 1, abstr)